Synergy Software / GE Healthcare / Becton-Dickinson Biosciences / Bio-Rad / Knudsen / Jackson ImmunoResearch Laboratories / Wiley-Liss Inc. / Masiello / Lehmann / AstraZeneca / Microsoft / Wiley InterScience / /
Continent
North America / /
Country
France / United Kingdom / Finland / Germany / / /
Event
Business Partnership / FDA Phase / /
Facility
Kuopio University / Centre Universitaire / /
IndustryTerm
media-binding buffer / neoadjuvant protocol / treatment of metastatic prostate cancer / prostate cancer therapy / chemical castration / therapy for localized and locally advanced prostate cancer / treatment protocol / therapy for locally advanced prostate cancer / cDNA product / mg/ml solution / /
MedicalCondition
metastatic prostate cancer / hormone sensitive breast cancer / JE / another AR-negative prostate cancer cell line / prostate cancers / prostate cancer cells expressing / negative prostate cancer / routine prostate cancer / prostate cancer / breast cancer / prostate carcinomas / tumor / additive tumor / cancer / tumors / S phase depression / efficient disease / ER-positive breast cancer / advanced prostatic carcinoma / good disease / metastasis / early prostate cancer / MS / primary tumors / Breast cancers / disease / prostate adenocarcinoma / prostatic carcinoma / high-risk prostate cancer / both hormone sensitive cancers / human prostate cancer / human prostate carcinoma / prostate carcinoma / /
The Prostate Antagonistic Interaction Between BicalutamideTM (Casodex1) and Radiation in Androgen-Positive Prostate Cancer LNCaP Cells Laurent Que´ro,1,2,3 Nicole Giocanti,1,2 Christophe Hennequin,1,2,3